Eloxx Pharmaceuticals Reports Topline Results from Phase II Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

Eloxx Pharmaceuticals, Inc. announced topline results from the Phase II clinical trial of ELX-02 in combination with ivacaftor in Class 1 CF patients with at least one nonsense mutation.